Metformin and cancer therapy.

Frédéric Bost*, Issam Ben Sahra, Yannick Le Marchand-Brustel, Jean François Tanti

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations

Abstract

To focus on the potential role of metformin, a widely used antidiabetic drug, in cancer treatment. Epidemiological, preclinical and cellular studies have shown in the last 6 years that metformin exerts antitumoral properties. Here, we review the very last findings concerning metformin action in cancer. The results of the first clinical trials as well as the combined action of metformin and chemotherapeutics agents in vitro and in vivo will be discussed. Recent studies show that metformin could also regulate inflammation and, therefore, may play a role in tumor microenvironment. Finally, we will present the latest publications concerning the molecular mechanisms implicated in metformin action, especially the AMP-activated kinase-independent pathways. The numerous in-vitro and in-vivo studies warrant the ongoing clinical trials, which should definitively help us to determine if metformin could be used in cancer therapy.

Original languageEnglish (US)
Pages (from-to)103-108
Number of pages6
JournalCurrent opinion in oncology
Volume24
Issue number1
StatePublished - Jan 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metformin and cancer therapy.'. Together they form a unique fingerprint.

Cite this